FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of biochemistry, in particular to radioimmunoconjugate, which binds human CD37. Radioimmunoconjugate includes murine monoclonal antibody HH1, chelating linker and radionuclide 177Lu and is applied for treatment of B-cell neoplasias. Also claimed are: pharmaceutical composition, containing said radioimmunoconjugate, method of treating B-cell neoplasia, for instance Non-hodgkin's lymphoma and chronic lympholeucosis, as well as set for manufacturing radioimmunoconjugate.
EFFECT: invention provides considerable cytotoxicity with respect to tumour cells.
14 cl, 8 dwg, 5 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL RADIOIMMUNOCONJUGATES AND USE THEREOF | 2011 |
|
RU2664475C1 |
| CHIMERIC THERAPEUTIC ANTI-CD-37 ANTIBODY HH1 | 2012 |
|
RU2658438C2 |
| METHOD FOR UPREGULATING ANTIGEN EXPRESSION | 2014 |
|
RU2681953C2 |
| DECREASING B-CELL COUNT WITH USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | 2006 |
|
RU2423381C2 |
| IMMUNOTHERAPY OF MALIGNANT DISEASES OF B-CELLS AND AUTOIMMUNE DISEASES WITH APPLICATION OF CONJUGATE AND NONCONJUGATE ANTIBODIES, COMBINATIONS OF ANTIBODIES AND CONJOINT PROTEINS | 2003 |
|
RU2335297C2 |
| CD37 BINDING MOLECULES AND IMMUNOCONJUGATES | 2011 |
|
RU2610662C9 |
| COMBINATION OF ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND MOLECULE BINDING TO B-CELLS, B-CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART | 2008 |
|
RU2484845C2 |
| ANTI-CD20 ANTIBODIES AND THEREOF APPLICATION | 2011 |
|
RU2573994C2 |
| ANTIBODIES POLYPEPTIDES AND USE THEREOF | 2014 |
|
RU2687163C1 |
| USING ANTI-CD40-ANTIBODIES | 2008 |
|
RU2491095C2 |
